NicaraguaTuberculosis profile
Population  2016 6.1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.16 (0.11–0.21) 2.6 (1.8–3.4)
Mortality (HIV+TB only) 0.028 (0.02–0.038) 0.46 (0.32–0.62)
Incidence  (includes HIV+TB) 2.9 (2.2–3.7) 48 (36–60)
Incidence (HIV+TB only) 0.14 (0.1–0.17) 2.2 (1.7–2.8)
Incidence (MDR/RR-TB)** 0.053 (0.013–0.093) 0.86 (0.21–1.5)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.15 (0.11–0.19) 0.95 (0.72–1.2) 1.1 (0.83–1.4)
Males 0.16 (0.12–0.2) 1.7 (1.2–2.1) 1.8 (1.4–2.3)
Total 0.31 (0.23–0.39) 2.6 (2–3.3) 2.9 (2.2–3.7)
TB case notifications, 2016  
Total cases notified 2 406
Total new and relapse 2 339
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 91%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 77%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.06 (0.04–0.09)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 99 5%
          - on antiretroviral therapy 99 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  42
(14–70)
Estimated % of TB cases with MDR/RR-TB 0.94% (0–2.3) 12% (7.3–18)  
% notified tested for rifampicin resistance 77% 135% 1 965
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 19, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 19, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 87% 2 464
Previously treated cases, excluding relapse, registered in 2015 75% 81
HIV-positive TB cases registered in 2015 58% 64
MDR/RR-TB cases started on second-line treatment in 2014 73% 15
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 6%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
32% (30–35)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data